Search Results 2521-2530 of 18312 for rheumatoid arthritis

  1. Overview - Neurobiology of Alzheimer's Disease and Related Dementias - Mayo Clinic Research

    The team seeks to understand why APOE2 contributes to longevity and protects against Alzheimer's disease; whereas, APOE4 is the strongest genetic risk factor ...

  2. Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye - Mayo Clinic

    ... factor/receptor (VEGF/R), and the chemotherapy agents temozolomide and dacarbazine; prior treatment must have been no earlier than 3 weeks prior to starting ...

  3. Program on Physician Well-Being - Research Translated Into Strategies in Practice

    ... factor loading on the emotional exhaustion and depersonalization subscales of the Maslach Burnout Inventory. The two items have been validated in a sample ...

  4. Hematology - Clinical trials

    The purpose of this study is to learn about how platelets adhere to the blood von Willebrand factor and how known clinical mutations that result in bleeding ...

  5. Publications - Steven Attia, D.O. - Mayo Clinic

    ... Factor Pathway in Angiosarcoma. Front Oncol. 2018; 8:71 Epub 2018 Mar 22. View PubMed; Bagaria SP, Chang YH, Gray RJ, Ashman JB, Attia S, Wasif N. Improving ...

  6. Peripheral artery disease (PAD) - Doctors and departments - Mayo Clinic

    Vascular Medicine Specialist. Phoenix, AZ. Areas of focus: Cardiovascular disease prevention, Joint injection, Physical examination, Preventive care, Arthritis, ...

  7. Postherpetic neuralgia - Symptoms and causes - Mayo Clinic

    This complication of shingles can cause pain, itching and numbness long after the shingles rash clears. Treatments can ease symptoms.

  8. Cardiomyopathy Clinical Trials - Mayo Clinic Research

    The blood tests involve analysis for von Willebrand Factor antigen and activity, von Willebrand Factor multimers, and brain natriuretic peptide (BNP) levels.

  9. Knee Biologic Preservation: Functional and Clinical Outcome

    Arthritis; Infection. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date information ...

  10. Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorder - Mayo Clinic

    Hematopoietic growth factors: ≥ 14 days after the last dose of a long-acting growth factor (e.g., Neulasta) or 7 days for short-acting growth factor; for ...